XML 84 R51.htm IDEA: XBRL DOCUMENT v2.4.1.9
DEFERRED REVENUE (Details) (USD $)
12 Months Ended 1 Months Ended 0 Months Ended 1 Months Ended
Dec. 31, 2014
Dec. 31, 2013
Dec. 31, 2012
Jul. 31, 2005
Dec. 31, 2004
Oct. 01, 2014
Jul. 31, 2008
Aug. 31, 2012
Jul. 31, 2011
Deferred revenue, current portion:                  
Deferred license revenue, current portion   $ 3,041,000depo_DeferredLicenseRevenueCurrent              
Deferred revenue, current portion   3,041,000us-gaap_DeferredRevenueCurrent              
Deferred license revenue, non-current portion:                  
Deferred license revenue, non-current portion   12,475,000us-gaap_DeferredRevenueNoncurrent              
Total deferred revenue   15,516,000us-gaap_DeferredRevenue              
Additional information                  
Revenue recognized 31,515,000us-gaap_LicenseAndServicesRevenue 12,796,000us-gaap_LicenseAndServicesRevenue 18,798,000us-gaap_LicenseAndServicesRevenue            
Valeant Pharmaceuticals International, Inc.                  
Deferred revenue, current portion:                  
Deferred license revenue, current portion   1,598,000depo_DeferredLicenseRevenueCurrent
/ us-gaap_CounterpartyNameAxis
= depo_ValeantPharmaceuticalsInternationalIncMember
             
Deferred license revenue, non-current portion:                  
Deferred license revenue, non-current portion   10,905,000us-gaap_DeferredRevenueNoncurrent
/ us-gaap_CounterpartyNameAxis
= depo_ValeantPharmaceuticalsInternationalIncMember
             
Additional information                  
Upfront fee received       25,000,000depo_UpfrontAgreementFeeReceived
/ us-gaap_CounterpartyNameAxis
= depo_ValeantPharmaceuticalsInternationalIncMember
25,000,000depo_UpfrontAgreementFeeReceived
/ us-gaap_CounterpartyNameAxis
= depo_ValeantPharmaceuticalsInternationalIncMember
       
Revenue recognized 12,500,000us-gaap_LicenseAndServicesRevenue
/ us-gaap_CounterpartyNameAxis
= depo_ValeantPharmaceuticalsInternationalIncMember
1,600,000us-gaap_LicenseAndServicesRevenue
/ us-gaap_CounterpartyNameAxis
= depo_ValeantPharmaceuticalsInternationalIncMember
1,600,000us-gaap_LicenseAndServicesRevenue
/ us-gaap_CounterpartyNameAxis
= depo_ValeantPharmaceuticalsInternationalIncMember
           
Valeant Pharmaceuticals International, Inc. | 1000mg Glumetza                  
Additional information                  
Revenue recognized           11,300,000us-gaap_LicenseAndServicesRevenue
/ us-gaap_CounterpartyNameAxis
= depo_ValeantPharmaceuticalsInternationalIncMember
/ us-gaap_ProductOrServiceAxis
= depo_Glumetza1000MgMember
     
Salix Pharmaceuticals, Inc. (formerly Santarus Inc.) | Commercialization Agreement                  
Additional information                  
Revenue recognized 3,000,000us-gaap_LicenseAndServicesRevenue
/ us-gaap_CounterpartyNameAxis
= depo_SalixPharmaceuticalsIncMember
/ us-gaap_TypeOfArrangementAxis
= depo_CommercializationAgreementMember
1,400,000us-gaap_LicenseAndServicesRevenue
/ us-gaap_CounterpartyNameAxis
= depo_SalixPharmaceuticalsIncMember
/ us-gaap_TypeOfArrangementAxis
= depo_CommercializationAgreementMember
3,300,000us-gaap_LicenseAndServicesRevenue
/ us-gaap_CounterpartyNameAxis
= depo_SalixPharmaceuticalsIncMember
/ us-gaap_TypeOfArrangementAxis
= depo_CommercializationAgreementMember
           
Salix Pharmaceuticals, Inc. (formerly Santarus Inc.) | Promotion Agreement                  
Additional information                  
Upfront fee received             12,000,000depo_UpfrontAgreementFeeReceived
/ us-gaap_CounterpartyNameAxis
= depo_SalixPharmaceuticalsIncMember
/ us-gaap_TypeOfArrangementAxis
= depo_PromotionAgreementMember
   
Revenue recognized           1,900,000us-gaap_LicenseAndServicesRevenue
/ us-gaap_CounterpartyNameAxis
= depo_SalixPharmaceuticalsIncMember
/ us-gaap_TypeOfArrangementAxis
= depo_PromotionAgreementMember
     
Santarus                  
Deferred revenue, current portion:                  
Deferred license revenue, current portion   1,443,000depo_DeferredLicenseRevenueCurrent
/ us-gaap_CounterpartyNameAxis
= depo_SantarusIncMember
             
Deferred license revenue, non-current portion:                  
Deferred license revenue, non-current portion   1,570,000us-gaap_DeferredRevenueNoncurrent
/ us-gaap_CounterpartyNameAxis
= depo_SantarusIncMember
             
Santarus | Promotion Agreement                  
Additional information                  
Upfront fee received             12,000,000depo_UpfrontAgreementFeeReceived
/ us-gaap_CounterpartyNameAxis
= depo_SantarusIncMember
/ us-gaap_TypeOfArrangementAxis
= depo_PromotionAgreementMember
   
Janssen Pharmaceuticals, Inc.                  
Additional information                  
Upfront fee received               10,000,000depo_UpfrontAgreementFeeReceived
/ us-gaap_CounterpartyNameAxis
= depo_JanssenPharmaceuticalsIncMember
 
Ironwood Pharmaceuticals, Inc.                  
Additional information                  
Upfront fee received                 $ 900,000depo_UpfrontAgreementFeeReceived
/ us-gaap_CounterpartyNameAxis
= depo_IronwoodPharmaceuticalsIncMember